Novo Nordisk shares rise as Wegovy updates improve earnings outlook

Novo Nordisk reported that recent data on its obesity drug Wegovy were less negative than expected, helping the company’s earnings.

The improved outlook lifted Novo Nordisk’s share price, narrowing the gap with rival Eli Lilly in the U.S. obesity market.

The company continues to benefit from the strong U.S. launch of Wegovy, which has become a major revenue driver.

Analysts noted that while the news is not a full approval update, the positive earnings impact underscores the drug’s commercial momentum.